Over 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, Actelion Pharmaceuticals, Eisai, GSK, and the U.S. FDASOUTH SAN FRANCISCO, Calif., Sept. 18, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that Douglas B. Snyder, joined the company as its Senior Vice President, General Counsel on September 18, 2024. "Doug brings a broad legal background in the healthcare field spanning biotechnology, pharm

LONDON, Dec. 3, 2020 /PRNewswire/ -- 2021 could be a big year for this soon-to-be $16-trillion biotech opportunity. More importantly, it could be a big year for companies pioneering a new form of therapy that could effectively treat the world's #1 disability. It's a disability that's costing the economy $1 trillion in lost production every single year. In fact, the revolutionary treatment could be at our doorstep by 2021. And the next few months are critical.   Mentioned in today's commentary includes:  Constellation Brands, Inc. (NYSE: STZ), Molson Coors Beverage Company (NYSE: TAP), Altria Group, Inc. (NYSE: MO), GW Pharmaceuticals plc (NASDAQ: GWPH), Curaleaf Holdings, Inc. (OTCQX: CUR

SC 13G/A - GW PHARMACEUTICALS PLC (0001351288) (Subject)

SC 13G/A - GW PHARMACEUTICALS PLC (0001351288) (Subject)

SC 13G - GW PHARMACEUTICALS PLC (0001351288) (Subject)

SC 13G - GW PHARMACEUTICALS PLC (0001351288) (Subject)

SC 13G/A - GW PHARMACEUTICALS PLC (0001351288) (Subject)

Raymond James resumed coverage of GW Pharmaceuticals with a rating of Hold

Citigroup downgraded GW Pharmaceuticals from Buy to Neutral

HC Wainwright downgraded GW Pharmaceuticals from Buy to Neutral

Morgan Stanley downgraded GW Pharmaceuticals from Overweight to Equal-Weight and set a new price target of $220.00 from $193.00 previously

HC Wainwright & Co. downgraded GW Pharmaceuticals from Buy to Neutral and set a new price target of $220.00 from $162.00 previously

SVB Leerink downgraded GW Pharmaceuticals from Outperform to Market Perform and set a new price target of $220.00 from $200.00 previously

Morgan Stanley downgraded GW Pharmaceuticals from Overweight to Equal Weight

Cantor Fitzgerald downgraded GW Pharmaceuticals from Overweight to Neutral

Northland Securities downgraded GW Pharmaceuticals from Outperform to Market Perform

Needham downgraded GW Pharmaceuticals from Buy to Hold

15-12B - GW PHARMACEUTICALS PLC (0001351288) (Filer)

S-8 POS - GW PHARMACEUTICALS PLC (0001351288) (Filer)

S-8 POS - GW PHARMACEUTICALS PLC (0001351288) (Filer)

S-8 POS - GW PHARMACEUTICALS PLC (0001351288) (Filer)

POSASR - GW PHARMACEUTICALS PLC (0001351288) (Filer)

8-K - GW PHARMACEUTICALS PLC (0001351288) (Filer)

25-NSE - GW PHARMACEUTICALS PLC (0001351288) (Subject)

10-K/A - GW PHARMACEUTICALS PLC (0001351288) (Filer)

8-K - GW PHARMACEUTICALS PLC (0001351288) (Filer)

DEFA14A - GW PHARMACEUTICALS PLC (0001351288) (Filer)

Over 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, Actelion Pharmaceuticals, Eisai, GSK, and the U.S. FDASOUTH SAN FRANCISCO, Calif., Sept. 18, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that Douglas B. Snyder, joined the company as its Senior Vice President, General Counsel on September 18, 2024. "Doug brings a broad legal background in the healthcare field spanning biotechnology, pharm

DUBLIN, May 5, 2021 /PRNewswire/ -- Jazz Pharmaceuticals (NASDAQ:JAZZ) today announced the completion of its acquisition of GW Pharmaceuticals plc (NASDAQ:GWPH) ("GW"), a leader in the science, development and commercialization of cannabinoid-based prescription medicines. "We are excited to welcome our GW colleagues to Jazz as we mark a transformative milestone in creating an innovative, high-growth, global biopharma leader in neuroscience with a worldwide commercial and operational footprint," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals. "The addition of GW further diversifies our commerical portfolio and innovative pipeline with therapies that are compl

LONDON, April 29, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH) ("GW", "the Company" or "the Group"), a world leader in discovering, developing and commercialising regulatory approved cannabis-based medicines, announces that it has received the Queen's Award for Enterprise 2021 in the Innovation category, recognising GW's innovative and ground-breaking work to harness cannabinoid science to create the world's first regulatory approved, prescription cannabis-based medicines. Since its inception in 1998, GW has successfully navigated significant barriers to enable the development, manufacture and commercialisation of regulatory approved cannabis-based medicines, leading the

LONDON and DUBLIN, April 23, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH) (GW) and Jazz Pharmaceuticals plc (NASDAQ:JAZZ) (Jazz) today announced that GW's shareholders voted to approve the acquisition of GW by a subsidiary of Jazz (or its nominee(s)) at the GW shareholder meetings held today. The proposals required to be approved by GW's shareholders in order to complete the acquisition were each approved. In addition, the non-binding, advisory proposal to approve certain compensation arrangements for GW's named executive officers was approved. Detailed information regarding the results will be made available by GW in a filing with the U.S. Securities and Exchange Commissi

– Tuberous sclerosis complex (TSC) represents a third indication for GW's cannabidiol in Europe – – TSC causes epilepsy in up to 85% of patients, and up to 60% of those patients do not respond to standard anti-epileptic medicines1,2,3 – LONDON, April 20, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH) ("GW", "the Company" or "the Group"), a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines, today announces that the European Commission (EC) has approved the Type II variation application for EPIDYOLEX® (cannabidiol) as an adjunctive treatment of seizures associated with TSC, for patients two years of age and older. This approv

EPIDOLEX encore presentations highlight long-term safety and efficacy data in patients with tuberous sclerosis complex (TSC) and other treatment-resistant epilepsies Nabiximols data show efficacy and safety results in patients with spasticity associated with multiple sclerosis CARLSBAD, Calif., April 13, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S. subsidiary Greenwich Biosciences, announced today that the company will present results from completed trials of EPIDIOLEX® (cannabidiol) oral solution and nabiximols, known as Sativex® outside of the U.

LONDON, Feb. 26, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines, today announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on the Company’s Type II variation application for EPIDYOLEX® (cannabidiol) as an adjunctive treatment of seizures associated with Tuberous Sclerosis Complex (TSC), for patients two years of age and older. TSC is a condition that causes mostly benign tumours to grow in vital organs of the body, including the brain, skin, heart, ey

LONDON, Feb. 26, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines, today announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on the Company’s Type II variation application for EPIDYOLEX® (cannabidiol) as an adjunctive treatment of seizures associated with Tuberous Sclerosis Complex (TSC), for patients two years of age and older. TSC is a condition that causes mostly benign tumours to grow in vital organs of the body, including the brain, skin, heart, ey

– Total revenue of $148.2 million for the fourth quarter and $527.2 million for the full year – – Total Epidiolex® net product sales of $144.1 million for the fourth quarter and $510.5 million for the full year – – Previously announced agreement to be acquired by Jazz Pharmaceuticals; transaction expected to close in Q2 2021 – LONDON and CARLSBAD, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced financial results and operating progress for the fourth quarter and full-year ended December 31, 2020. “We are very proud of our stron

DUBLIN and LONDON, Feb. 3, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and GW Pharmaceuticals plc (Nasdaq: GWPH) today announced the companies have entered into a definitive agreement for Jazz to acquire GW for $220.00 per American Depositary Share (ADS), in the form of $200.00 in cash and $20.00 in Jazz ordinary shares, for a total consideration of $7.2 billion, or $6.7 billion net of GW cash. The transaction, which has been unanimously approved by the Boards of Directors of both companies, is expected to close in the second quarter of 2021. Upon close of the transaction, the combined company will be a leader in neuroscience with a global commercial and operational footp